ClinicalTrials.gg
RecruitingNCT06300177Updated Apr 26, 2024

D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure

A Phase 3 interventional study of D-1553 Tablet and Docetaxel injection in Non Small Cell Lung Cancer, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Recruiting at 86 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-26.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
522
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies in Carcinoma, Non-Small-Cell Lung by Sino Biopharmaceutical Limited — 8 open to participants now, 8 under way, 4 of them phase 3. Carcinoma, Non-Small-Cell Lung · Sino Biopharmaceutical Limited.

Planned enrollment
2nd of 27
522 · median 117
Started
2024
with 2 others
Phase 3
9 of 27
4 open now
Registered
22nd of 27
by date

Among the 27 studies in Carcinoma, Non-Small-Cell Lung by Sino Biopharmaceutical Limited, this one is the 2nd largest by planned enrollment, is one of 3 that started in 2024, is one of 9 in phase 3, and was the 22nd registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

8 of the 27 studies in Carcinoma, Non-Small-Cell Lung by Sino Biopharmaceutical Limited are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Carcinoma, Non-Small-Cell Lung by Sino Biopharmaceutical Limited, or all of them as a file.
02

Study summary

The purpose of this project is to evaluate progression-free survival (PFS) of D-1553 Tablet versus Docetaxel Injection in subjects with prior standard therapy failure kirsten rat sarcoma viral oncogene (KRAS) G12C mutation positive locally advanced or metastatic non small cell lung cancer (NSCLC), progression-free survival (PFS) as assessed by the Independent Review Committee (IRC) based on RECIST 1.1 was used as the primary endpoint.

03

Conditions studied

  • Non Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntary participation in the study and sign of written after full informed consent, willing and able to comply with the study procedures and requirements specified in the protocol;
  • Age greater than or equal to 18 years old; male and female; performance status (ECOG) score 0-1; expected survival period greater than or equal to 3 months;
  • confirmed locally advanced, unresectable and / or non-small cell lung cancer (stage III b / III c / IV of american joint committee on cancer (AJCC) 8th);
  • Subjects must provide adequate and qualified tumor tissue specimens (surgical resection samples or puncture / tissue samples within 2 years prior to screening) for confirmation of the KRAS G12C mutation in the central laboratory;
  • Disease progression or toxicity after previous treatment with / PD-L1 and platinum-containing chemotherapy is not tolerated.Subjects who have clear medical reasons and can not tolerate anti-PD-1 / PD-L1 therapy or platinum-containing chemotherapy;
  • Having at least one target lesion according to 1.1;
  • Good function of the major organs;
  • Female subjects of childbearing age should agree that must be used during the study and within 6 months after the end of the study; the serum pregnancy test is negative within 7 days before study enrollment and must be non-lactating subjects; male subjects should agree that contraception must be used during the study and within 6 months after the end of the study period.

Exclusion criteria

Exclusion Criteria:

  • Treatment with a KRAS G12C mutation inhibitor or docetaxel at any previous time;
  • NSCLC with mutations of other driver genes;
  • Symptomatic or progressive aggravation of central nervous system or cancerous meningitis. Subjects with a history of may be considered to be selected if they are clinically stable;
  • Patients with a previous history of epilepsy;presence of superior vena cava syndrome;
  • Cardiovascular system meets any condition:

    1. (NYHA) Heart Function Grade II and above congestive heart failure;
    2. Severe cardiac arrhythmias requiring medical treatment;
    3. Acute myocardial infarction, severe or unstable angina pectoris, coronary or peripheral artery bypass surgery within 6 months prior to enrollment;
    4. (LVEF) \<50%;
    5. (QTcF) at prolonged;
    6. Hypertension that is not effectively controlled;
  • Subjects with stroke or other severe cerebrovascular disease within 6 months before enrollment;
  • History of deep vein thrombosis or any other serious thromboembolism within 3 months prior to enrollment;
  • History of interstitial lung disease, radiation pneumonitis, and immune-associated pneumonia previously treated with , Or active non-infectious pneumonia with interstitial lung disease, radiation pneumonia, and immune-related pneumonia during the screening period, Presence of active tuberculosis, pneumoconiosis or grade 2 other type of pneumonia, or pulmonary function tests confirming severely impaired pulmonary function;
  • Severe bone damage due to tumor bone metastasis may occur at present or after randomization;
  • Active or uncontrolled serious infection (≥grade 2 infection of common toxicity criteria for adverse events (CTC AE)) or fever of unknown origin > 38.5°C;
  • The third space effusion (including pleural effusion, abdominal effusion or pericardial effusion), poor clinical control or the need for local symptomatic treatment such as puncture and drainage;
  • Known impaired gastrointestinal (GI) function or known GI diseases that may significantly affect the absorption or metabolism of oral drugs.

Previous history of major surgery in the digestive tract (esophagus, gastrointestinal tract) that may alter the absorption or inability to swallow drugs in the study treatment;

  • Toxicity of previous antitumor therapy, except alopecia, pigmentation, clinically insignificant laboratory abnormalities) has not recovered to grade 1, and peripheral nerve toxicity has not recovered to grade 2 ( v5.0);
  • (HIV) antibody positive, liver cirrhosis or active viral hepatitis;
  • Active syphilis;
  • Patients with renal failure requiring hemodialysis or peritoneal dialysis;
  • Poor diabetes control [fasting blood glucose (FBG)> 10 mmol/L];
  • Previous history of organ transplantation or readiness to undergo organ transplantation;
  • Weight of \<40 kg and of \<18.5 kg/m2, or weight loss of> 5% within 3 months before enrollment;
  • Major surgical treatment or significant traumatic injury within 4 weeks prior to the first dose of this study;
  • Receiving palliative radiotherapy with local lesions within 2 weeks before the first dose of this study;
  • Pregnant or lactating subjects;
  • With the combination of other primary
  • Serious mental or mental illness or history of substance abuse or serious alcohol abuse;
  • Known allergy to the medicinal product or any ingredient in the formulation;
  • Any other significant clinical abnormality or disease that the investigator considers poses a risk to subject safety or interferes with the medication and evaluation of the clinical study.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
522 participants (estimated)

Study arms

  • Experimental
    D-1553 Tablet

    D-1553 Tablet,21 days as a treatment cycle.

    Drug: D-1553 Tablet

  • Active comparator
    Docetaxel Injection

    Docetaxel Injection,21 days as a treatment cycle.

    Drug: Docetaxel injection

Interventions

  • D-1553 is a KRAS inhibitor.

  • Docetaxel, is an anti-tumor drug, significantly reduces the number of free tubules by promoting tubule polymerization into stable microtubules and inhibiting their depolymerization.

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS)

    Time from subject randomization (first treatment) to first disease progression or death from any cause, whichever occurred first, was assessed by an independent Review Committee (IRC) per Response evaluation criteria in solid tumors (RECIST) 1.1.

    Time frame: Baseline up to 3 years

Secondary outcomes

  1. Overall survival (OS)

    From randomization to the time of death from any cause.

    Time frame: Baseline up to 3 years

  2. Objective mitigation rate (ORR)

    According to RECIST 1.1 criteria, proportion of patients with confirmed tumor volume reduction to pre-specified values and maintained minimum requirements , namely the proportion of patients with complete response (CR) and partial response (PR).

    Time frame: Baseline up to 3 years

  3. Duration of Response (DOR)

    From the time of tumor first evaluated as complete or partial response to the time of first disease progression or death from various causes.

    Time frame: Baseline up to 3 years

  4. Disease control rate (DCR)

    According to RECIST 1.1 criteria, proportion of patients with confirmed tumor volume reduction to pre-specified values and maintained minimum requirements , namely the proportion of patients with CR, PR and stable disease (SD).

    Time frame: Baseline up to 3 years

  5. Time to response (TTR)

    Time from patient randomization (first treatment) to first response per RECIST 1.1 criteria

    Time frame: Baseline up to 3 years

  6. Patient-reported outcome (PRO)

    Reports of their health status directly from patients

    Time frame: Baseline up to 3 years

  7. Abnormal laboratory test indicators

    The occurrence of laboratory test indicators exceed the normal range

    Time frame: From the subject signed the informed consent form to 30 days after the last dose

  8. Adverse event rate

    The occurrence of all adverse events (AEs), serious adverse events (SAEs) and treatment-related adverse events (TEAEs)

    Time frame: From the subject signed the informed consent form to 30 days after the last dose

  9. Time to Maximum Plasma Concentration (Tmax)

    Time to maximum plasma concentration after dosing

    Time frame: Pre-dose and 2 hours after D1553 administration on Day 1 of cycle 1 and cycle 3. Each cycle is 21 days.

  10. Half life (t1/2)

    Time required for plasma concentrations to drop by half

    Time frame: Pre-dose and 2 hours after D1553 administration on Day 1 of cycle 1 and cycle 3. Each cycle is 21 days.

07

Study locations

1 of 86 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Oct 2026, 31 months after the start.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's planned 31 months is below that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2024
First posted
Mar 8, 2024
StartActual
Mar 28, 2024
Primary completionEst.
Oct 2026
CompletionEst.
Dec 2027
Last update
Apr 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06300177
Responsible party
Sponsor
First posted
Mar 8, 2024
Start date
Mar 28, 2024
Primary completion
Oct 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
Apr 26, 2024

Study contacts

Shun Lu, Doctor
Contact
shun_lu@hotmail.com
13601813062

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Garsorasib

Start the discussion